At 5.2% CAGR, the SAM Laboratory Animal Diet Market is projected to be worth US$ 384.49 million by 2028, says Business Market Insights

According to Business Market Insights’ research, the SAM laboratory animal diet market was valued at US$ 284.86 million in 2022 and is expected to reach US$ 384.49 million by 2028, registering a CAGR of 5.2% from 2022 to 2028. Growing consumption of personalized medicines and rising usage of mice models in virology and infectious diseases are the critical factors attributed to the market expansion.    

Medicine is moving away from the "one size fits all" paradigm. The vision of personalized medicine for the 21st century is to provide the right patient with the right drug in the correct dose at the right time. The practical application of personalized medicine depends heavily on the availability of rigorous diagnostic tools that allow the optimal selection of therapeutic products to improve patient outcomes. According to the Food and Drug Administration (FDA), personalized medicine aims to increase benefits and reduce patient risks by targeting prevention and treatment more effectively. Personalized medicines are treatments based on the environment, the patient's unique biological makeup, and lifestyle. Companies are focused on introducing new companion diagnostics for various types of cancer.  Personalized medicines are concepts, practices, or modalities that expressly predict the human response to medicines and diseases based on intraspecific differences. Slight differences in genetic makeup can result in dramatic differences in response to drugs or disease. Researchers help in developing approaches to personalized medicines for many genetic disorders. These personalized medicines sometimes use custom genetic interventions, such as antisense-mediated exon skipping or genome editing, to restore protein function in a mutation-specific manner. In drug discovery and development, mice models have played an essential role by characterizing disease pathophysiology and associated injury mechanisms, identifying drug targets, and evaluating novel therapeutics for toxicity/safety, pharmacokinetics, pharmacodynamics, and efficacy. The specific model chosen for a particular drug to be tested and developed depends on the goal of the thorough study. The traditional use of animal models in drug discovery establishes and demonstrates non-clinical proof of concept for specific drug molecules' safety, efficacy, and target of interest. Animal models can facilitate the development of personalized medicine approaches. Personalized medicine approaches need to be developed and preclinically tested in relevant cell and mouse models that ideally contain the human target sequences. The animal models used for personalized medicine research and drug discovery & development are provided with specific diets so that the animal model will react according to the human environment. Therefore, with the rising demand for personalized medicines, the Laboratory Animal Diet market is growing substantially.

On the contrary, high cost of laboratory animal diets due to maintenance and wastage hurdles the growth of SAM laboratory animal diet market.    

Based on diet type, the SAM laboratory animal diet market is segmented into standard diets, irradiated diets, and autoclavable diets. The standard diets segment held 67.7% market share in 2022, amassing US$ 192.96 million. It is projected to garner US$ 256.76 million by 2028 to expand at 4.9% CAGR during 2022–2028.  

Based on animal, the SAM laboratory animal diet market is segmented into mouse, cat, dog, rabbit, chicken, and others. The mouse segment held 53.9% market share in 2022, amassing US$ 153.59 million. It is projected to garner US$ 211.67 million by 2028 to expand at 5.5% CAGR during 2022–2028.

Based on application, the SAM laboratory animal diet market is segmented into drug discovery and personalized medicines, regenerative medicines, pathology of infectious disease, drug toxicity and efficacy testing, and others. The drug discovery and personalized medicine segment held 48.6% market share in 2022, amassing US$ 138.33 million. It is projected to garner US$ 181.64 million by 2028 to expand at 4.6% CAGR during 2022–2028.

Based on end user, the SAM end user market is segmented into pharmaceutical & biopharmaceutical companies, research & academic institutes, and others. The pharmaceutical & biopharmaceutical companies segment held 63.4% market share in 2022, amassing US$ 180.73 million. It is projected to garner US$ 241.41 million by 2028 to expand at 4.9% CAGR during 2022–2028.

Based on country, the SAM laboratory animal diet market is segmented into Brazil, Argentina, and the Rest of SAM. Our regional analysis states that Rest of SAM captured 38.0% market share in 2022. It was assessed at US$ 108.33 million in 2022 and is likely to hit US$ 143.45 million by 2028, exhibiting a CAGR of 4.8% during the forecast period.    

Key players dominating the SAM laboratory animal diet market are Altromin Spezialfutter GmbH & Co. KG; Bio-Serv; Envigo; LabDiet; Research Diets Inc.; SAFE; Special Diet Services; and Specialty Feeds among others.  

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com